Table A1.
Stratified analyses for significant interaction terms (stratified at the median, intention-to-treat analyses).
| N | Two-Year Change Scores in the Fully Adjusted Models Mean (95% CI) | F a | p | |
|---|---|---|---|---|
| GDS-15: Stratified analyses for folate: | ||||
| Low Folate: (≤18.86 nmol/L) | 1.63 | 0.21 | ||
| B-vitamins | 38 | 1.87 (0.76, 2.98) | ||
| Placebo | 41 | 0.86 (−0.21, 1.92) | ||
| High Folate: (>18.86 nmol/L) | 3.47 | 0.07 | ||
| B-vitamins | 38 | 1.19 (0.17, 2.20) | ||
| Placebo | 41 | 2.53 (1.56, 3.51) | ||
| GDS-15: Stratified analyses for MMA: | ||||
| Low MMA: (≤0.23 µmol/L) | 2.70 | 0.10 | ||
| B-vitamins | 38 | 0.63 (−0.50, 1.76) | ||
| Placebo | 41 | 1.95 (0.87, 3.04) | ||
| High MMA: (>0.23 µmol/L) | 1.12 | 0.29 | ||
| B-vitamins | 38 | 2.28 (1.34, 3.22) | ||
| Placebo | 41 | 1.57 (0.67, 2.48) | ||
| GDS-15: Stratified analyses for Vitamin B12: | ||||
| Low Vitamin B12: (≤266.4 pmol/L) | 1.07 | 0.30 | ||
| B-vitamins | 41 | 2.14 (1.13, 3.16) | ||
| Placebo | 39 | 1.36 (0.32, 2.41) | ||
| High Vitamin B12: (>266.4 pmol/L) | 4.52 | 0.04 | ||
| B-vitamins | 41 | 0.55 (−0.60, 1.69) | ||
| Placebo | 39 | 2.21 (1.18, 3.24) | ||
| EQ-5D VAS: Stratified analyses for sex: | ||||
| Men: | 2.75 | 0.10 | ||
| B-vitamins | 657 | −0.86 (−1.73, 0.02) | ||
| Placebo | 667 | −1.90 (−2.76, −1.03) | ||
| Women: | 1.07 | 0.30 | ||
| B-vitamins | 645 | −1.33 (−2.32, −0.33) | ||
| Placebo | 643 | −0.58 (−1.58, 0.42) | ||
a Differences between the two treatment groups over time were tested with ANCOVA, adjusted for baseline values of the respective outcome variable, age, sex, homocysteine, and study center. GDS-15: Geriatric Depression Scale 15-item version; MMA: methylmalonic acid; EQ-5D VAS: EuroQol 5 Dimensions—Visual Analogue Scale.